Show Summary Details
Page of

Ocular infections 

Ocular infections
Chapter:
Ocular infections
DOI:
10.1093/med/9780198729228.003.0016
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 18 November 2019

Immunocompromised children are at an increased risk for infection. The different categories of both primary and acquired secondary immunodeficiencies largely influence the patient´s vulnerability to a specific pathogen and also determine the clinical presentation. Primary immunodeficiencies are usually unknown at the first presentation of a child, and investigations regarding immunodeficiency should be considered in children with recurrent, severe, or unusual infections. The most important principle of treatment in patients with a suspected or proven immunodeficiency is the prompt initiation of antimicrobial treatment. The regimen has to include agents against the most likely pathogens but also has to consider the local epidemiology and pattern of resistance. Depending on the type of immunodeficiency, antimicrobial prophylaxis is another mainstay of infection control in immunocompromised patients and may include non-pharmacological measures, the use of immunomodulatory compounds, and pharmacologic prophylaxis using antimicrobial compounds.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.